Kausik Ray: Phase 1 Trial Highlights Anti-Inflammatory Effects of Ruvonoflast
Kausik Ray, Professor of Public Health at Imperial College London, Past President of European Atherosclerosis Society, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in JACC Journals, adding:
“Ruvonoflast reduced hsCRP in patients with elevated inflammatory risk.
We just published the phase 1 data.
Ongoing Phase 2 trials.”
Title: Anti-inflammatory effects of oral NLRP3 inhibition with ruvonoflast among individuals at elevated cardiovascular risk
Authors: Kausik K. Ray, Nicholas Clarke, Peter Thornton, Amy E. Miles, Zsofia Digby, Melanie J. Davies, Michelle Gorman, Bianca Mullen, Valérie Reader, Missy Magill, Hilary Johnstone, Cono Ariti, Naveed Sattar, Nikolaus Marx, Ann Marie Navar, Adrian F. Hernandez, Jyothis T. George, Alan P. Watt, Javed Butler, Paul M. Ridker
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 20, 2026, 02:37M. Sekip Altunkan: Can Anticoagulation Be Safely Stopped After AF Ablation?
-
Oct 20, 2026, 02:26Ahmed Ammar: Managing VT Recurrence Post-Ablation
-
Oct 20, 2026, 01:43Oliver Weingärtner: Deprescribing of Lipid Lowering Drug after MI is Associated with Cardiovascular Events
-
Oct 19, 2026, 19:44Where You Live Should not Determine Whether You Receive Care – World Federation of Hemophilia
-
Oct 19, 2026, 19:42Belen Bianco: Prevention, Early Suspicion and an Interdisciplinary Approach Save Lives
-
Oct 19, 2026, 19:40Christina Chrysohoou: Catheter-Based LAAC vs OAC for Stroke Prevention in Atrial Fibrillation
-
Oct 19, 2026, 19:38Matthew Flick: A Two-Day Research Meeting on Fibrinogen, Hemostasis and Thrombosis
-
Oct 19, 2026, 19:37Hayat Saeed: Excited to Share Our Publication on the FGL1–Hepcidin Axis in Iron Homeostasis and Disease
-
Oct 19, 2026, 19:08IPAW 2026 Comes to a Close, but the Work Continues – PPTA